Copyright
©The Author(s) 2019.
World J Gastrointest Surg. Sep 27, 2019; 11(9): 365-372
Published online Sep 27, 2019. doi: 10.4240/wjgs.v11.i9.365
Published online Sep 27, 2019. doi: 10.4240/wjgs.v11.i9.365
Table 1 Baseline characteristics of the study cohort, n (%)
Percutaneous | Laparoscopic | Open Surgical | P value | |
n = 347 | n = 248 | n = 107 | ||
Age | 0.64 | |||
18-35 | 56 (16.1) | 33 (13.3) | 13 (12.1) | |
36-60 | 175 (50.4) | 137 (55.2) | 55 (51.4) | |
60 + | 116 (33.4) | 78 (31.5) | 39 (36.4) | |
Sex | 0.15 | |||
Male | 220 (63.4) | 158 (63.7) | 66 (61.7) | |
Female | 126 (36.3) | 90 (36.3) | 41 (38.3) | |
Race | 0.53 | |||
White | 224 (64.6) | 169 (68.1) | 70 (65.4) | |
Black | 50 (14.4) | 28 (11.3) | 15 (14.0) | |
Hispanic | 39 (11.2) | 20 (8.1) | 14 (13.1) | |
Asian-Pacific Islander | 9 (2.6) | 3 (1.2) | 2 (1.9) | |
Other | 14 (4.0) | 13 (5.2) | 2 (1.9) | |
Admission type | < 0.001 | |||
Emergency | 318 (53.4) | 212 (35.6) | 65 (10.9) | |
Non-emergency | 26 (25.0) | 36 (34.6) | 42 (40.4) | |
Hospital type | < 0.001 | |||
Urban teaching | 280 (47.6) | 227 (38.6) | 81 (13.8) | |
Urban non-teaching | 58 (60.4) | 19 (19.8) | 19 (19.8) | |
Rural | 9 (50) | 2 (11.1) | 7 (38.9) | |
Primary payer | 0.42 | |||
Medicare | 111 (32.0) | 62 (25.0) | 35 (32.7) | |
Medicaid | 71 (20.5) | 57 (23.0) | 24 (22.4) | |
Private | 121 (34.9) | 103 (41.5) | 36 (33.6) | |
Other | 44 (12.7) | 26 (10.5) | 12 (11.2) | |
Pancreatitis type | 0.06 | |||
Acute | 164 (47.3) | 89 (35.9) | 35 (32.7) | |
Acute on chronic | 84 (24.2) | 71 (28.6) | 25 (23.4) | |
Chronic | 38 (11.0) | 36 (14.5) | 17 (15.9) | |
Charlson Comorbidity index | 0.77 | |||
0 | 126 (36.3) | 103 (41.5) | 45 (42.1) | |
1-2 | 189 (54.5) | 123 (49.6) | 56 (52.3) | |
3-4 | 30 (8.6) | 21 (8.5) | 6 (5.6) | |
≥ 5 | 2 (0.6) | 1 (0.4) | 0 (0.0) |
Table 2 Specific comorbidities of the study cohort, n (%)
Percutaneous | Laparoscopic | Surgical | P value | |
n = 347 | n = 248 | n = 107 | ||
Acute myocardial infarction | 15 (4.3) | 8 (3.2) | 5 (4.7) | 0.74 |
Congestive heart failure | 31 (8.9) | 19 (7.7) | 4 (3.7) | 0.21 |
Peripheral vascular disease | 15 (4.3) | 7 (2.8) | 3 (2.8) | 0.56 |
Cerebrovascular disease | 6 (1.7) | 3 (1.2) | 1 (0.9) | 0.78 |
Dementia | 2 (0.6) | 3 (1.2) | 0 (0.0) | 0.42 |
Chronic obstructive pulmonary disease | 58 (16.7) | 43 (17.3) | 16 (15.0) | 0.86 |
Rheumatoid disease | 11 (3.2) | 3 (1.2) | 0 (0.0) | 0.07 |
Peptic ulcer disease | 10 (2.9) | 13 (5.2) | 3 (2.8) | 0.28 |
Mild liver disease | 52 (15.0) | 36 (14.5) | 9 (8.4) | 0.21 |
Diabetes without complications | 105 (30.3) | 61 (24.6) | 32 (29.9) | 0.29 |
Diabetes with complications | 12 (3.5) | 11 (4.4) | 5 (4.7) | 0.77 |
Hemiplegia or paraplegia | 3 (0.9) | 0 (0.0) | 0 (0.0) | 0.21 |
Renal disease | 33 (9.5) | 24 (9.7) | 4 (3.7) | 0.14 |
Cancer (any malignancy) | 15 (4.3) | 6 (2.4) | 4 (3.7) | 0.46 |
Moderate or severe liver disease | 10 (2.9) | 17 (6.9) | 7 (6.5) | 0.06 |
Metastatic solid tumour | 6 (1.7) | 2 (0.8) | 0 (0.0) | 0.28 |
AIDS/HIV | 2 (0.6) | 1 (0.4) | 0 (0.0) | 0.72 |
Table 3 Procedure related complications, n (%)
Complications | Percutaneous | Laparoscopic | Open surgical | P value |
n = 347 | n = 248 | n = 107 | ||
Transfusion of RBC | 39 (11.2) | 7 (2.8) | 20 (18.7) | < 0.001a |
Transfusion of FFP | 4 (1.2) | 4 (1.6) | 4 (3.7) | 0.19 |
Transfusion of Platelet | 2 (0.6) | 0 (0.0) | 0 (0.0) | 0.36 |
Mechanical ventilation | 37 (10.7) | 18 (7.3) | 12 (11.2) | 0.31 |
Pulmonary embolism | 11 (3.2) | 5 (2.0) | 2 (1.9) | 0.60 |
Acute deep vein thrombosis | 3 (0.9) | 3 (1.2) | 0 (0.0) | 0.52 |
Acute renal failure | 84 (24.2) | 49 (19.8) | 12 (11.2) | 0.01a |
Urinary tract infection | 34 (9.8) | 12 (4.8) | 2 (1.9) | 0.01a |
Pneumonia | 21 (6.1) | 8 (3.2) | 6 (5.6) | 0.28 |
Sepsis | 109 (31.4) | 34 (13.7) | 23 (21.5) | < 0.001a |
Acute hepatic failure | 5 (1.4) | 6 (2.4) | 1 (0.9) | 0.53 |
Acute respiratory failure | 60 (17.3) | 24 (9.7) | 9 (8.4) | 0.01a |
Exacerbation of heart failure | 19 (5.5) | 13 (5.2) | 2 (1.9) | 0.30 |
Cardiac arrest | 5 (1.4) | 3 (1.2) | 0 (0.0) | 0.47 |
Intraabdominal abscess | 34 (9.8) | 14 (5.6) | 8 (7.5) | 0.18 |
Table 4 Inpatient outcome of the study cohort, n (%)
Table 5 Multivariable regression of length of stay and total charge
Standardized coefficient for length of stay | P value | Standardized coefficient for total charge | P value | |
Type of pancreatitis | ||||
Acute pancreatitis | Reference | Reference | Reference | Reference |
Chronic pancreatitis | -0.197 | < 0.001 | -0.172 | < 0.001 |
Acute on chronic pancreatitis | -0.130 | < 0.001 | -0.148 | 0.001 |
Hospital type | ||||
Urban teaching | Reference | Reference | Reference | Reference |
Urban non-teaching | -0.054 | 0.19 | 0.009 | 0.82 |
Rural | -0.044 | 0.291 | -0.046 | 0.277 |
Drainage type | ||||
Laparoscopic | Reference | Reference | Reference | Reference |
Non-laparoscopic | 0.135 | 0.001 | 0.102 | 0.017 |
- Citation: Wang Y, Omar YA, Agrawal R, Gong Z. Comparison of treatment modalities in pancreatic pseudocyst: A population based study. World J Gastrointest Surg 2019; 11(9): 365-372
- URL: https://www.wjgnet.com/1948-9366/full/v11/i9/365.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v11.i9.365